U.S. Patient and Trademark Office, U.S. DEPARTMENT OF COMMERCE.
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Application Number	- 1	10390747	
	Filing Date			
INFORMATION DISCLOSURE	First Named Inventor KLEE,		et al.	
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit		1751	
	Examiner Name			
	Attorney Docket Numbe	r	08563-0188-U1	

U.S.PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue [	Date	Name of Pate of cited Docu	entee or Applicant ment	Releva		ines where es or Relev	
	1	4539382		1985-0	9-03	Omura et al.					
	2	6172131	B1	2001-0	1-09	Moszner et al.					
If you wis	h to a	i dd additional U.S. Pater	nt citatio	n inform	ation pl	lease click the	Add button.		Add		_
			U.S.P	ATENT	APPLI	CATION PUBI	LICATIONS		Remove		-
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publica Date	ation	of cited Document		Releva	Pages,Columns,Lines where Relevant Passages or Relevant rigures Appear		
	1	20020016384	A1	2002-0	2-07	Moszner et al.					
	2	20030167968	A1	2003-0	9-11	Erdmann et al	L				
If you wisl	h to a	l dd additional U.S. Publi	shed Ap	plication	citatio	n information p	olease click the Ad	d buttor	n. Add		_
				FOREIG	GN PAT	ENT DOCUM	ENTS		Remove		=
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>			Publication Date Name of Patentee or Applicant of cited Document		e or	Pages,Colu where Rele Passages of Figures Ap	vant or Relevant	тя
	1	03/013444 A1	wo		A1	2003-02-20	Dentsply Internation	nal,			
					1	1	1				

### 

A1

2000-03-02 Biomat Services, Inc.

wo

2 00/10478

	3	03/035013	wo	A1	2003-05-01	Dentsply Detrey GmbH		
	4	1 454 911	EP	A1	2004-09-08	Dentsply Detrey GmbH		
	5	199 18 974	DE	A1	1999-12-16	Degussa-Huls AG		
	6	1 548 021	ΕP	A1	2005-06-29	Dentsply Detrey GmbH		
	7	197 46 708	DE	A1	1999-04-22	Ivoctar AG		
	8	1 148 060	EP EP	A1	2001-10-24	Ivoclar Vivadent AG		
	9	1 169 996	EP EP	A1	2002-01-09	Ernst Muhlbauer KG		
If you wis	h to a	dd additional Foreign P				ease click the Add buttor		
NON-PATENT LITERATURE DOCUMENTS Remove								
Examiner Initials* Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.								Тs
N. Mozner, F. Zeuner, U.K. Fischer, V. Rhenberger, Monomers for Adhesive Polymers, 2A: Synthesis and Radical Polymerzolation of Hydrolytically Stable Acrylic Phosphonic Acids, Macromol. Chem. Phys., 1999, pp. 1052-1067, vol. 200, No. 5								

If you wish to add additional non-patent literature document citation information please click the Add button Add

	Application Number		10596747	
INFORMATION DIGGS COURT	Filing Date			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	First Named Inventor KLEE		et al.	
	Art Unit		1751	
	Examiner Name			
	Attorney Docket Numb	er	08563-0188-U1	

EXAMINER SIGNATURE						
Examiner Signature		Date Considered				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a						

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Kind Codes of USPTO Patent Documents at were USPTO.GCV or MPEP 901.04. <sup>2</sup> Enter office that seased the document, by the he-letter code (WIPO Standard ST3). <sup>2</sup> For Japanese patent document, be enabled to the codes of the year of the region of the Emperor may precede the sensi number of the patent document. Affect of document by the appropriate sprinces are included to the Code of the Co

English language translation is attached.

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10596747
Filing Date		
First Named Inventor	KLEE	, et al.
Art Unit		1751
Examiner Name		
Attorney Docket Numb	er	08563-0188-U1

#### CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):	
---	--

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(a)(1).

#### OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(s)(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Brian T. Sattizahn/	Date (YYYY-MM-DD)	2006-09-28
Name/Print	Brian T. Saftizahn	Registration Number	46401

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 GA 37 CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. O. Box 1430, Alexandriu, V.S. 2213.1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandriu, V.S. 2213.1450.

## Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.